CDC’s Walensky Suggests Higher Bar May Be Needed For Fourth COVID Vaccine Shots
Pfizer and Moderna have both indicated a fourth mRNA COVID vaccine may be needed. Companies may need to show waning protection against severe disease first.
You may also be interested in...
US FDA adds a warning about immune thrombocytopenia, joining the risk of Thrombosis with Thrombocytopenia Syndrome.
Decision to allow boosters for 12- to 15-year-old recipients of the Pfizer/BioNTech vaccine will go before CDC's ACIP, but like several other recent changes for COVID vaccines, the US FDA opted to skip its advisory committee.
If regulators agree with Pfizer’s conclusions – and briefing documents suggest that’s a big if – about real-world studies showing Comirnaty’s effectiveness waning over time, thereby justifying the need for a booster dose, it could be part of a historical moment for FDA’s use of RWE.